Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Former OtisMed CEO Sentenced To Two Years For Selling FDA-Rejected Knee Devices

This article was originally published in The Gray Sheet

Executive Summary

The sentencing, which also includes an additional one year of supervised release and a $75,000 fine, concludes a long-running investigation into the firm, which is now a subsidiary of Stryker.

You may also be interested in...



DOJ Manual Updated To Enhance Focus On Targeting Individual Execs

The updated US Attorney’s Manual instructs government lawyers to focus on individuals from the launch of civil or criminal investigations into a company, and not to consider individual’s ability to pay a judgment in deciding whether to pursue charges.

Stryker's OtisMed Pleads Guilty For Selling FDA-Rejected Cutting Guides

The unit and its former CEO admitted to selling knee-replacement instruments even after FDA rejected a 510(k), prior to OtisMed being acquired by Stryker in 2009. The legal resolution comes with about $80 million in fines and possible jail time for the former CEO. Also, Stryker has agreed to conduct an audit on the FDA approval status of devices in its portfolio.

US FDA Not Changing Assessment Goals Because of Coronavirus-Mandated Telework

Assessment work also isn’t slowing down, the new and generic drug office directors said in an interview, but approval data offers a note of concern.

Topics

Related Companies

UsernamePublicRestriction

Register

MT033998

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel